+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmacogenomics Services Market - Global Forecast 2026-2032- Product Image
Pharmacogenomics Services Market - Global Forecast 2026-2032- Product Image
Sale

Pharmacogenomics Services Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6160254
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Pharmacogenomics Services: Executive Overview

Pharmacogenomics services apply genetic information to help assess how individuals may respond to medicines, supporting treatment selection, dosing decisions, and adverse-event risk management. The field brings together laboratory testing, clinical interpretation, decision-support tools, and implementation services across healthcare, research, and drug-development settings. Its strategic importance is increasing as health systems pursue more personalized and evidence-based care, while also addressing validation, reimbursement, privacy, and workflow-integration requirements.

Clinical Integration Is Reshaping Pharmacogenomics Services

The landscape is shifting from standalone genetic testing toward integrated clinical pathways that connect sample collection, laboratory analysis, interpretation, prescribing guidance, and longitudinal record management. Adoption increasingly depends on analytical validity, clinical utility, transparent evidence, interoperability, and the ability to embed results into prescribing workflows. Regulation, professional guidance, reimbursement policies, and patient consent practices remain decisive factors in determining how services move from specialist programs into routine care.

Artificial Intelligence Strengthens Interpretation and Workflow Efficiency

Artificial intelligence can support pharmacogenomics services by organizing variant evidence, prioritizing clinically relevant findings, identifying potential drug-gene interactions, and generating structured summaries for clinician review. It may also improve quality assurance, automate administrative workflows, and help reconcile laboratory results with medication histories and clinical context. However, AI outputs require expert oversight, traceable sources, representative validation data, cybersecurity controls, and clear accountability because errors in interpretation can affect treatment decisions.

Regional Differences Reflect Policy, Infrastructure, and Health-System Readiness

North America is characterized by comparatively mature clinical, research, and laboratory infrastructure, although reimbursement and implementation practices vary across jurisdictions. Europe combines advanced genomics capabilities with strong privacy and regulatory expectations, while the European Union faces the practical challenge of aligning approaches across health systems. Asia-Pacific includes highly developed precision-medicine ecosystems alongside markets where laboratory capacity and access remain uneven. Latin America is shaped by concentrated specialist capacity, public-sector constraints, and expanding interest in locally relevant genomic evidence. The Middle East is investing in genomics infrastructure and national health initiatives, while the African region continues to address access, workforce, data representation, and locally appropriate validation.

International Groups Balance Shared Standards with Uneven Implementation

ASEAN countries face diverse healthcare infrastructures and regulatory environments, making interoperable standards, workforce development, and regional evidence collaboration particularly important. BRICS members bring substantial scientific and population diversity but differ widely in laboratory capacity, reimbursement, and data-governance models. The European Union emphasizes privacy, cross-border health-data governance, and harmonized clinical quality. G7 economies generally have strong research and healthcare capabilities, yet still confront integration and reimbursement barriers. GCC countries are advancing centralized health strategies and genomic infrastructure, while NATO members must consider secure data exchange, resilient supply chains, and the ethical use of genomic information across allied systems.

Country-Level Priorities Vary Across Infrastructure, Policy, and Clinical Adoption

Australia is focused on integrating genomics into geographically dispersed healthcare systems. Brazil and Mexico are balancing specialist capacity with broader public-health access. Canada is emphasizing evidence-based implementation across a federated healthcare structure. China is expanding precision-medicine capabilities while managing regulatory and data-governance requirements. France, Germany, Italy, Spain, and the United Kingdom are developing clinical pathways within distinct national reimbursement, privacy, and health-service frameworks. India is addressing scale, affordability, workforce development, and population diversity. Japan and South Korea combine advanced healthcare and technology capabilities with aging-population considerations. Russia’s development is influenced by laboratory infrastructure, regulatory conditions, and access to validated clinical resources. Across the United States, clinical adoption is supported by extensive research and laboratory activity but remains sensitive to payer coverage, workflow integration, and evidence requirements.

Leadership Priorities for Reliable Pharmacogenomics Deployment

Industry leaders should begin with clearly defined clinical use cases where pharmacogenomic information can affect prescribing decisions, then establish evidence thresholds, confirmatory processes, and measurable outcomes. Services should use validated assays, transparent interpretation frameworks, interoperable reporting, and decision support that fits existing clinical workflows. Organizations should also build multidisciplinary governance covering clinicians, laboratory specialists, genetic counselors, pharmacists, privacy experts, and patient representatives. Responsible deployment requires robust consent, secure data handling, bias monitoring, clinician education, and post-implementation evaluation. Partnerships with health systems, regulators, researchers, and patient communities can improve relevance while reducing fragmentation across testing and care pathways.

Methodology for the Pharmacogenomics Services Assessment

This executive summary uses a structured qualitative assessment of pharmacogenomics services across clinical, laboratory, research, regulatory, technological, and health-system dimensions. The analysis compares the supplied regional, group, and country geographies by considering publicly established factors such as healthcare infrastructure, genomics capability, policy environment, data governance, workforce readiness, and implementation barriers. It emphasizes verifiable structural insights rather than numerical market estimates. Findings should be interpreted as a strategic synthesis; detailed decisions require review of current regulatory guidance, clinical evidence, reimbursement rules, and institution-specific operating conditions.

A Disciplined Path from Genetic Insight to Better Medication Decisions

Pharmacogenomics services are evolving toward integrated, evidence-led capabilities that connect genetic testing with practical prescribing decisions. Progress will depend less on testing alone than on clinical utility, trustworthy interpretation, equitable access, interoperability, and sustained professional confidence. Artificial intelligence can accelerate these capabilities when deployed with validation and oversight. Organizations that align technology with governance, patient protection, workforce readiness, and measurable clinical objectives will be better positioned to translate pharmacogenomic information into safer and more individualized medication management.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Pharmacogenomics Services Market, by Test Type
7.1. Introduction
7.2. Panel Test
7.2.1. Comprehensive Gene Panel
7.2.2. Small Gene Panel
7.3. Single Gene Test
7.4. Whole Genome Sequencing
8. Pharmacogenomics Services Market, by Technology
8.1. Introduction
8.2. Microarray
8.3. Ngs
8.3.1. Targeted Ngs
8.3.2. Whole Exome Sequencing
8.3.3. Whole Genome Sequencing
8.4. Pcr
9. Pharmacogenomics Services Market, by Application Area
9.1. Introduction
9.2. Cardiovascular
9.3. Infectious Disease
9.4. Neurology
9.5. Oncology
9.6. Pharmacokinetic
10. Pharmacogenomics Services Market, by End User
10.1. Introduction
10.2. Academic Research Centers
10.2.1. Research Institutes
10.2.2. Universities
10.3. Diagnostic Laboratories
10.4. Hospitals
10.5. Pharmaceutical Companies
11. Pharmacogenomics Services Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Pharmacogenomics Services Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Pharmacogenomics Services Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. 23andMe, Inc.
15.2. Abbott Laboratories
15.3. Bio-Rad Laboratories, Inc.
15.4. F. Hoffmann-La Roche Ltd.
15.5. Illumina, Inc.
15.6. Invitae Corporation
15.7. Laboratory Corporation of America Holdings
15.8. Myriad Genetics, Inc.
15.9. QIAGEN N.V.
15.10. Quest Diagnostics Incorporated
15.11. Thermo Fisher Scientific Inc.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Pharmacogenomics Services Market, Years Considered for the Study
FIGURE 2. Global Pharmacogenomics Services Market, Research Design
FIGURE 3. Global Pharmacogenomics Services Market, Research Framework
FIGURE 4. Global Pharmacogenomics Services Market, Data Triangulation
FIGURE 5. Global Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Pharmacogenomics Services Market Size, by Test Type, 2025 vs 2032 (%)
FIGURE 7. Global Pharmacogenomics Services Market Size, by Test Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Pharmacogenomics Services Market Size, by Technology, 2025 vs 2032 (%)
FIGURE 9. Global Pharmacogenomics Services Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Pharmacogenomics Services Market Size, by Application Area, 2025 vs 2032 (%)
FIGURE 11. Global Pharmacogenomics Services Market Size, by Application Area, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Pharmacogenomics Services Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Pharmacogenomics Services Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Pharmacogenomics Services Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Pharmacogenomics Services Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Pharmacogenomics Services Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Pharmacogenomics Services Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Pharmacogenomics Services Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Pharmacogenomics Services Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Pharmacogenomics Services Market Segmentation & Coverage
TABLE 2. Global Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 3. Global Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 4. Global Panel Test Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Panel Test Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Panel Test Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Comprehensive Gene Panel Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Comprehensive Gene Panel Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Comprehensive Gene Panel Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Small Gene Panel Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Small Gene Panel Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Small Gene Panel Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Single Gene Test Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Single Gene Test Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Single Gene Test Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Whole Genome Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Whole Genome Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Whole Genome Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 20. Global Microarray Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Microarray Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Microarray Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Ngs Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Ngs Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Ngs Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Targeted Ngs Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Targeted Ngs Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Targeted Ngs Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Whole Exome Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Whole Exome Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Whole Exome Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Whole Genome Sequencing Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Whole Genome Sequencing Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Whole Genome Sequencing Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Pcr Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Pcr Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Pcr Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 39. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Infectious Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Infectious Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Infectious Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Neurology Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Neurology Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Neurology Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Pharmacokinetic Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Pharmacokinetic Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Pharmacokinetic Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 55. Global Academic Research Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Academic Research Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Academic Research Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Universities Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Universities Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Universities Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Pharmacogenomics Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Pharmacogenomics Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 82. North America Pharmacogenomics Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. North America Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 84. North America Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 85. North America Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 86. North America Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 87. North America Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 88. North America Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. North America Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 90. Latin America Pharmacogenomics Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Latin America Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 92. Latin America Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 93. Latin America Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 94. Latin America Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 95. Latin America Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 96. Latin America Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 97. Latin America Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 98. Europe Pharmacogenomics Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Europe Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 100. Europe Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 101. Europe Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 102. Europe Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 103. Europe Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 104. Europe Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Europe Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 106. Middle East Pharmacogenomics Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Middle East Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 108. Middle East Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 109. Middle East Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 110. Middle East Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 111. Middle East Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 112. Middle East Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 113. Middle East Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 114. Africa Pharmacogenomics Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Africa Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 116. Africa Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 117. Africa Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 118. Africa Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 119. Africa Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 120. Africa Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 121. Africa Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 122. Global Pharmacogenomics Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. ASEAN Pharmacogenomics Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. ASEAN Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 125. ASEAN Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 126. ASEAN Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 127. ASEAN Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 128. ASEAN Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 129. ASEAN Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. ASEAN Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 131. GCC Pharmacogenomics Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. GCC Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 133. GCC Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 134. GCC Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 135. GCC Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 136. GCC Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 137. GCC Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. GCC Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 139. European Union Pharmacogenomics Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. European Union Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 141. European Union Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 142. European Union Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 143. European Union Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 144. European Union Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 145. European Union Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. European Union Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 147. BRICS Pharmacogenomics Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. BRICS Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 149. BRICS Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 150. BRICS Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 151. BRICS Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 152. BRICS Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 153. BRICS Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. BRICS Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 155. G7 Pharmacogenomics Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 156. G7 Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 157. G7 Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 158. G7 Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 159. G7 Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 160. G7 Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 161. G7 Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. G7 Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 163. NATO Pharmacogenomics Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 164. NATO Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 165. NATO Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 166. NATO Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 167. NATO Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 168. NATO Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 169. NATO Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. NATO Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 171. Global Pharmacogenomics Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 172. United States Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 173. United States Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 174. United States Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 175. United States Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 176. United States Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 177. United States Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 178. United States Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 179. United States Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 180. Canada Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 181. Canada Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 182. Canada Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 183. Canada Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 184. Canada Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 185. Canada Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 186. Canada Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. Canada Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 188. Mexico Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 189. Mexico Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 190. Mexico Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 191. Mexico Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 192. Mexico Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 193. Mexico Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 194. Mexico Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. Mexico Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 196. Brazil Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 197. Brazil Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 198. Brazil Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 199. Brazil Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 200. Brazil Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 201. Brazil Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 202. Brazil Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. Brazil Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 204. United Kingdom Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 205. United Kingdom Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 206. United Kingdom Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 207. United Kingdom Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 208. United Kingdom Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 209. United Kingdom Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 210. United Kingdom Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. United Kingdom Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 212. Germany Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 213. Germany Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 214. Germany Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 215. Germany Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 216. Germany Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 217. Germany Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 218. Germany Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. Germany Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 220. France Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 221. France Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 222. France Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 223. France Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 224. France Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 225. France Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 226. France Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. France Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 228. Russia Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 229. Russia Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 230. Russia Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 231. Russia Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 232. Russia Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 233. Russia Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 234. Russia Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. Russia Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 236. Italy Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 237. Italy Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 238. Italy Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 239. Italy Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 240. Italy Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 241. Italy Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 242. Italy Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 243. Italy Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 244. Spain Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 245. Spain Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 246. Spain Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 247. Spain Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 248. Spain Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 249. Spain Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 250. Spain Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 251. Spain Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 252. China Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 253. China Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 254. China Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 255. China Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 256. China Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 257. China Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 258. China Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. China Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 260. India Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 261. India Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 262. India Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 263. India Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 264. India Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 265. India Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 266. India Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. India Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 268. Japan Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 269. Japan Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 270. Japan Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 271. Japan Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 272. Japan Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 273. Japan Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 274. Japan Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. Japan Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 276. Australia Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 277. Australia Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 278. Australia Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 279. Australia Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 280. Australia Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 281. Australia Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 282. Australia Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 283. Australia Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 284. South Korea Pharmacogenomics Services Market Size, 2017-2032 (USD Million)
TABLE 285. South Korea Pharmacogenomics Services Market Size, by Test Type, 2017-2032 (USD Million)
TABLE 286. South Korea Pharmacogenomics Services Market Size, by Panel Test, 2017-2032 (USD Million)
TABLE 287. South Korea Pharmacogenomics Services Market Size, by Technology, 2017-2032 (USD Million)
TABLE 288. South Korea Pharmacogenomics Services Market Size, by Ngs, 2017-2032 (USD Million)
TABLE 289. South Korea Pharmacogenomics Services Market Size, by Application Area, 2017-2032 (USD Million)
TABLE 290. South Korea Pharmacogenomics Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 291. South Korea Pharmacogenomics Services Market Size, by Academic Research Centers, 2017-2032 (USD Million)
TABLE 292. Global Pharmacogenomics Services Market Share, by Key Player, 2025
TABLE 293. Global Pharmacogenomics Services Market, Key Experts

Companies Mentioned

  • 23andMe, Inc.
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific Inc.

Related Topics

Related Reports

Pharmacogenomics Market - Global Forecast 2026-2032 - Product Image

Pharmacogenomics Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Pharmacogenomics Technology Market - Global Strategic Business Report - Product Image

Pharmacogenomics Technology Market - Global Strategic Business Report

  • Report
  • 291 Pages
  • Global
From
Pharmacogenomics Market Report 2026 - Product Image

Pharmacogenomics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Pharmacogenomics Technology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Pharmacogenomics Technology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 185 Pages
  • Global
From
Pharmacogenomics Testing Market - Strategic Insights and Forecasts (2026-2031) - Product Image

Pharmacogenomics Testing Market - Strategic Insights and Forecasts (2026-2031)

  • Report
  • 146 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.